Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-06-14 @ 4:44 AM
Study NCT ID:
NCT05198960
Status:
RECRUITING
Last Update Posted:
2025-02-04
First Post:
2021-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Sponsor:
University Hospital, Brest
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
29BRC20.0263 (AVAJAK)
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None